U.S. Pharma Manufacturing and R&D Site Investments Announced in 2025 and 2026

Pharma companies named 52 new or expanded US manufacturing and R&D sites between January 2025 and November 2026, with $66.1B in disclosed site-level investment, and Eli Lilly accounts for $25.5B of that total across 5 sites. The site announcements sit inside much larger company-level commitments, which add up to about $600B across 16 companies, although those pledges cover different periods and include R&D spending.
This review maps where the named sites are, what they will make, and how tariff and pricing policy shaped the timing of the announcements.

Where the sites are
California and North Carolina lead with 7 named projects each, followed by Indiana (5), Texas (4), and Pennsylvania (4), and Virginia, Maryland, Massachusetts, and Illinois have 3 each. The 52 projects span 20 states, so the investment is spread more widely than the traditional hubs in Massachusetts and New Jersey.
Several of the largest single sites are in states with little prior large-scale pharma manufacturing, including Lilly's $6B active ingredient plant in Huntsville, Alabama, and UCB's $2B biologics plant in Gwinnett County, Georgia, its first US manufacturing site.
The largest named site investments
| Company | Location | Focus | Announced amount | Announced |
|---|---|---|---|---|
| Eli Lilly | Houston, Texas | Small-molecule active ingredients, including orforglipron | $6.5B | Sep 2025 |
| Eli Lilly | Huntsville, Alabama | Small-molecule and peptide active ingredients | More than $6B | Dec 2025 |
| Eli Lilly | Goochland County, Virginia | Bioconjugates, antibody-drug conjugates, and antibodies | $5B | Sep 2025 |
| AstraZeneca | Albemarle County, Virginia | Drug substance for metabolic medicines and antibody-drug conjugates | $4.5B | Jul and Oct 2025 |
| Eli Lilly | Lebanon, Indiana | Active ingredients and genetic medicine | $4.5B (additional) | May 2026 |
| Eli Lilly | Fogelsville, Pennsylvania | Injectables and devices | More than $3.5B | Jan 2026 |
| Merck | Rahway, New Jersey | Research and clinical manufacturing | More than $3.5B | Oct 2025 |
| Merck | Elkton, Virginia | Small-molecule active ingredients and drug product | $3B | Oct 2025 |
| Bristol Myers Squibb | Houston, Texas | Small molecules, biologics, and antibody-drug conjugates | About $2.3B | Aug 2026 |
| Bayer | New Albany, Ohio | Drug substance and drug product | $2.2B | Oct 2026 |
What the sites will make
Active ingredients and obesity medicines account for much of the new capacity. Lilly's new sites in Texas ($6.5B) and Alabama (more than $6B) will produce small-molecule and peptide ingredients, including for orforglipron, and Genentech raised its Holly Springs, North Carolina investment for metabolic and obesity medicines from more than $700M to about $2B.
Biologics and newer modalities make up most of the rest. Merck's $1B site in Wilmington, Delaware will produce biologics including future US supply of Keytruda, AstraZeneca added antibody-drug conjugates to the scope of its $4.5B Virginia plant, and Novartis is adding radioligand therapy capacity across 5 sites in Florida, Texas, Indiana, New Jersey, and California.
Company-level commitments
| Company | US commitment | Period |
|---|---|---|
| AbbVie | $100B in R&D and capital | Next decade |
| Merck | More than $70B in manufacturing and R&D | From 2025 |
| Pfizer | An additional $70B in R&D and capital projects | Next few years |
| Johnson & Johnson | More than $55B | Through early 2029 |
| Roche | $50B | 5 years |
| AstraZeneca | $50B | By 2030 |
| Bristol Myers Squibb | $40B | 5 years |
| Gilead | $32B, of which $11B is new | Through 2030 |
| GSK | $30B | 5 years |
| Eli Lilly | More than $50B since 2020, of which $23B was committed by 2024 | Since 2020 |
| Novartis | $23B | 5 years |
| Sanofi | At least $20B | Through 2030 |
How policy shaped the announcements
The announcements followed the Commerce Department's Section 232 investigation into pharmaceutical imports, opened in April 2025, and the tariff proclamation signed on April 2, 2026, which set a 100% tariff on patented drugs, a 20% rate for companies with an approved US manufacturing plan, and no tariff until January 2029 for companies that also have a pricing agreement.
Companies tied many of their commitments to those pricing agreements, starting with Pfizer's additional $70B on September 30, 2025, and by September 2026 the White House counted 26 manufacturers with agreements covering 89% of the branded drug market.
Progress so far
Of the projects announced in 2025, 14 have broken ground and 5 are open or operating, including AstraZeneca's expanded Coppell, Texas plant and Novartis's radioligand therapy site in Carlsbad, California. Most of the other sites expect to start operating between 2027 and 2032, so the new capacity will arrive gradually over the rest of the decade.
Implications
The investments shift US capacity toward active ingredient production and obesity medicines first, and they spread it across 20 states. Many site amounts remain undisclosed, including Gilead's Foster City buildings and several Novartis and AstraZeneca sites, so the $66.1B figure understates total site-level spending.
Teams that monitor competitors' manufacturing and capacity investments often compare several intelligence platforms, and our guide to the best pharma competitive intelligence tools sets out the main options.
Methodology: The review covers US manufacturing and R&D sites with a named state and city announced between January 1, 2025 and November 10, 2026 by the 20 largest biopharma companies by revenue and other companies with a single US site of $1B or more, from company press releases and state economic development announcements. Puerto Rico projects, contract manufacturing agreements, and sites without a named location are excluded. Site totals use the latest company figure and the floor of "more than" amounts. Company-level commitments are as each company stated them, cover different periods, often include R&D, and overlap with the site amounts, and the about $600B total also includes Boehringer Ingelheim ($10B), Novo Nordisk ($10B, as reported by the White House), Regeneron ($9B), and CSL ($1.5B), with Lilly counted at $27B of new commitments.